IL22 and psoriasis: However, the loss of IL-36R signaling successfully counteracts and protects against the development of imiquimod-induced psoriasis compared to deletions of the IL-23/IL-17/IL-22 axis, indicating that IL-36 activity should be early in the cascade of psoriasis initiation [42,43,44,45].